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Abstract 
 
 
Introduction: The presence of JAK2 mutation is now a part of the 
essential diagnostic tools of Myeloproliferative disorders (MPDs); these 
types of haematological disorders are composed of Polycythaemia Vera 
(PRV), Essential Thrombocythaemia (ET) and Primary Myelofibrosis 
(PM). 
Objectives: 
General Objectives: To study the clinical and haematological features 
and to look for JAK 2 mutation in Sudanese patients with MPDs. 
Specific Objectives:  
- To describe the clinical features of MPDs in Sudanese patients. 
- To describe the haematological features of MPDs in Sudanese patients.  
- To detect the presence of the JAK 2 mutation in Sudanese patients with 
MPDs. 
- To correlate JAK2 mutation to clinical course of the disease. 
 
Method and materials: This is a cross sectional descriptive hospital 
based study carried out during the period from May 2010 to August 2010 
at Fedail and Khartoum Radio Isotope Centre haematology clinics. 
The study was designed to investigate the clinical, haematological and 
molecular findings in Sudanese patients with MPDs. 
Fifty patients were divided into 3 groups, patients with PRV (39), ET (9) 
and PM (2). Each group then was subdivided into those with positive 
JAK2 mutation and those with negative JAK2 mutation using DNA 
amplification techniques. The study included clinical data, blood and 
bone marrow examinations and molecular techniques. 
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Results: 39 patients (78%) had PRV, 9 (18%) had ET and 2 (4%) had 
PM. Among those patients with PRV, 25 patients (64.1%) presented 
initially with headache and dizziness, 2 (5.1%) with headache alone and 
12 (30.8%) were asymptomatic. 4 patients (44.5%) with ET presented 
with headache and dizziness, 3 (33.3%) with thrombotic complications 
and 2 (22.2%) were asymptomatic. 20 patients (51.3%) with PRV 
presented initially with splenomegaly and in 13 patients (33.3%) there 
was no organomegaly. 6 patients (66.7%) with ET presented with 
splenomegaly, 2 (22.2%) with hepatomegaly and one patient (11.1%) 
had no organomegaly. In patients with PM one presented with 
hepatosplenomegaly and the other one with splenomegaly only. 
The study also showed that among those patients with PRV, 16 patients 
(41%) had no fibrosis, 15 (38.5%) had grade 1 fibrosis and 8 patients 
(20.5%) had grade 2 & 3 fibrosis, while those with ET, 4 patients 
(44.5%) had grade 2fibrosis, 2 (22.2%)  had grade 1 fibrosis and 2 
patients (22.2%) had grade 3 fibrosis and one (11.1%) had grade 4 
fibrosis, while in those with PM, one (50%) patients had grade 3 fibrosis 
and one (50%) had grade 4 fibrosis. 
The study also showed that JAK2 mutation was present in 23 out of 39 
patients with PRV, 4 out of 9 patients with ET and no one with PM. It 
also shows among those patients with PRV who were JAK2V617F 
positive, 13 patients (56.5%) had some grade of fibrosis, while those 
patients with PRV who were JAK2V617F negative, 10 patients (62.5%) 
had some grade of fibrosis. Among those patients with ET who were 
JAK2V617F positive, 4 patients (100%) had significant grade of 
fibrosis, while those patients with ET who were JAK2V617F negative, 3 
patients (60%) had significant grade of fibrosis. Among those patients 
with PM who were JAK2V617F negative, 100% had significant grade 
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of fibrosis, while there was no patient with PM who was JAK2V617F 
positive. In patients with PRV who were JAK2V617F positive, the mean 
haemoglobin level was 17.04 g/dl, while those who were JAK2V617F 
negative the mean haemoglobin level for them was 16.74 g/dl. Patients 
with ET, who were JAK2V617F positive, had a mean haemoglobin level 
of 13.63 g/dl, while those JAK2V617F negative had a mean 
haemoglobin level of 12.66 g/dl. Patients with PM who were 
JAK2V617F negative had a mean haemoglobin level of 8.5 g/dl. There 
was no patient with PM who was JAK2V617F positive. 
Conclusion: This study showed that PRV was more prevalent than ET 
and PM. MPDs are more prevalent in the central part of the Sudan.The 
prevalence of JAK2 mutation in PRV is much less than that reported in 
the literature.         
 
The presence of JAK2V617F does not make any significant difference in 
the clinical presentation in those patients with PRV. 
The presence of a positive JAK2V617F mutation in patients with ET is 
associated with increased haemoglobin levels and is therefore increased 
risk of thrombosis.  
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CML            Chronic myelocytic leukaemia 
CMML Chronic myelomonocytic leukaemia 
EEC         Endogenous erythroid colony                                           
EPO   Erythropoietin 
ERO-R             Erythropoietin receptor 
ET                     Essential thrombocytosis 
IL                      Interleukin 
JAK2                Janus kinase 2 
MPDs                Myeloproliferative disorders 
PMF                  Primary myelofibrosis 
PRV                  Polycythaemiavera 
TPO                  Thrombopoietin 
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Introduction 
          
 
1.1 Myloproliferative disorders: 
The myeloproliferative disorders (MPDs) are group of haematological 
conditions where there is a primary disorder at the level of multi-potent 
haematopoietic stem cells leading to increased production in one or more 
blood cell types. The three main disorders in the group are polycythaemia 
vera (PV), essential thrombocythaemia (ET) and idiopathic myelofibrosis 
(IMF). PV is characterized by an increase in red cells, white cells and 
platelets, The annual incidence of PV is reported to be around 2–3 per100 
000 of the population with a male–female ratio of 0.8:1.2.The median age 
at onset is 55–60 years and although incidence increases with age, PV can 
occur at any age even, rarely, in childhood. Clinically patients presented 
with plethoric appearance, itching and splenomegaly. The disease can be 
complicated by thromboembolic phenomena which are the most common 
serious complication of PV. Untreated PV patients run a greatly increased 
risk of thrombosis, which can be arterial, venous or microvascular. The 
increased PCV leads to an increased blood viscosity, rheological 
abnormalities and abnormal platelet–endothelial contact. Additionally, 
procoagulant changes in platelets (e.g. decreased response to 
prostaglandin D2), thrombocytosis and pre-existing vascular disease can 
all conspire to dramatically increase thrombotic risk. Arterial occlusions 
can lead to myocardial infarcts, strokes, transient ischaemic attacks, 
amaurosis, scotomata, mesenteric and limb ischaemia. Less commonly, 
microvascular occlusions affecting the extremities and erythromelalgia 
can occur. In the venous circulation, unusual sites such as the splanchnic 
vessels are often involved. As a result, mesenteric, splenic and 
2 
 
hepatoportal thromboses are not uncommonly presenting features of  PV. 
Superficial thrombophlebitis, conventional deep venous thrombosis and 
pulmonary emboli are also seen. and haemorrhage and in the end stages 
can progress to myelofibrosis and acute leukaemia, a Progression to 
myelofibrosis occurs in around10–20% of PV cases at 15 years after 
diagnosis, while the risk of developing acute leukaemia in PV patients 
treated only with venesection  is very small (1–3%). This risk, however, 
increases dramatically (more than 10-fold) when radioactive phosphorus 
(32P), chlorambucil or irradiation are used as treatment. The diagnosis of 
PV requires both the exclusion of secondary and apparent polycythaemia, 
and the identification of positive criteria in support of PV. Bone marrow 
is hyperplastic with dominant erythroid hyperplasia and megakaryocyte 
clustering, sometime disfiguring the marrow architecture. 
   ET is characterized by an increased platelets count. Clinically it is 
frequently asymptomatic but the thromboembolic events may lead to 
disease detection thrombotic complications are the main cause of 
morbidity and mortality in ET. Thromboses are present in around 15–
20% of patients at presentation and may be arterial or venous. The range 
of clinical syndromes is similar to that of PV, but the frequency of 
splanchnic thrombosis is probably lower in ET.A number of risk factors 
are associated with an increase in the risk of thrombosis in patients with 
ET. The best characterized are age over 60 years and a prior history of 
thrombosis. Other risk factors for thrombosis in ET are likely to include 
high platelet count (> 1000), hyperlipidaemia, hypertension and cigarette 
smoking. Bleeding is less common and less well studied than thrombosis 
in ET, but can be dramatic when it happens , it is  more common in 
patients with platelet counts above 1000 and, in at least some cases, this 
is due to an acquired Von Willebrand  disease, with a decrease in high-
molecular-weight  multimers. Splenomegaly is present in about 20–25% 
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of ET patients at diagnosis and it is rarely more than moderate It has been 
suggested that over time, some patients with ET develop splenic atrophy 
secondary to silent microinfarcts in the splenic microcirculation. Frank 
hyposplenism and its complications are rare however. . There is a small 
propensity to progress to myelofibrosis (10%), PV (1-2%) and acute 
leukaemia which may be influenced by the treatment modalities used,  ET 
can evolve into a myelodysplastic syndrome (MDS) or AML even in 
untreated cases, but only rarely. The presence of cytogenetic 
abnormalities and treatment with alkylating agents increase this risk. 
Approximately 3% of patients treated with hydroxyurea alone develop 
MDS or AML if followed for a median time of 8 years.  Essential 
thrombocythaemia is a diagnosis of exclusion, 
the lack of pathognomonic features and the existence of many other 
causes of a raised platelet count pose significant hurdles in the diagnosis 
of ET.  Bone marrow histological features such as giant, multilobated 
megakaryocytes and megakaryocyte clustering are suggestive of ET. 
Bone marrow cytogenetic abnormalities are encountered in less than 5% 
of cases at diagnosis and, when present, are similar to those seen in PV. 
 IMF is defined by a leukoerythroblastic blood picture, splenomegaly and 
bone marrow fibrosis. The estimated annual incidence of IMF is around 
0.5–1.5 per 100 000 of the population,  The blood picture includes 
anaemia thrombocythaemia  or  thrombocytopnoea and variable white 
cells counts, the presence of myeloid and erythroid precursors in the 
peripheral blood (leucoerythroblastic blood picture) is common in IMF 
Teardrop poikilocytes (dacryocytes), basophilic stippling, macrocytosis 
(which may or may not be secondary to folate deficiency), giant platelets 
and megakaryocyte fragments may also be present. Attempts at bone 
marrow aspiration often yield a dry-tap or a haemodilute sample, making 
aspirate morphology of limited diagnostic value.  Bone marrow trephine 
4 
 
biopsy is essential to make a diagnosis of PMF. Initial stages are 
characterized by an increase in bone marrow cellularity in association 
with disorganization of marrow architecture and the presence of abnormal 
large megakaryocytes often occurring in clusters. Bone marrow fibrosis 
becomes increasingly dominant and progressively replaces haemopoiesis.  
Intrasinusoidal haemopoiesis can sometimes be seen at this stage . The 
degree of fibrosis is best demonstrated using silver impregnation, which 
stains reticulin fibres. Collagen fibres are best demonstrated using a 
trichrome stain. The degree of fibrosis can be graded from I to IV 
according to severity. In a minority of cases of advanced IMF (less than 
10%), osteosclerosis ensues with thickening of the trabecula and 
extensive deposition of osteoid. The disease frequently progresses 
inexorably to transfusion dependent anaemia, symptomatic splenomegaly 
and transformation to acute leukaemia, the presence of immature myeloid 
as well as erythroid progenitors is a characteristic feature of PMF . 
Neutrophilia is common, as are modest elevations in basophil and 
eosinophil counts. As the disease progresses, leucopenia increases in 
frequency and is believed to be secondary to progressive hypersplenism, 
dysmyelopoiesis and progressive replacement of the bone marrow by 
fibrotic tissue. In end-stage IMF, myeloid precursors become increasingly 
common relative to mature cells, as do circulating blasts. Transformation 
to AML occurs in 5–10%of cases of IMF and is usually rapidly fatal. 
The diagnosis of MPDs requires the integratioin of clinical and laborotary 
findings, bone marrow morphologic features and JAK-2 analysis.                     
A number of different biological phenomena have been described in 
haematopoietic cells from PV patients and others MPDs, the majority of 
which involve dysregulation of key signaling mediators. The key 
molecular events in the pathogenesis of these disorders have been poorly 
defined to date, except in the case of Chronic Myeloid Leukaemia (CML) 
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with the associated characteristic chromosomal translocation-the 
Philadelphia chromosome- and associated rearranged gene BCR – ABL. 
PV progenitor cells have been shown to grow in the absence of added 
erythropoietin, so called endogenous erythroid colony (EEC) formation 
and to be hypersensitive to a variety of other cytokines including insulin 
like growth factor-1. EEC however is not specific to PV but also 
identified in others MPDs. 
Over 50 years ago Dameshek linked together the recognized disorders 
PV, CML and IMF and speculated on the common myelostimulatory 
factors. In the early 1970s CML was separated as a distinct clonal 
disorder defined by a single chromosomal and literally gene 
rearrangement (BCR – ABL). Until very recently the other MPDs 
continue to be separated and diagnosed on the bases of their clinical and 
laboratory findings. However, recent molecular findings in the JAK2 
gene are common to all these disorders. 
The G-to-T point mutation at position 617 (V617F) in Janus kinase 2 
(JAK2) that results in substitution of phenylalanine for valine has been 
reported in patients withBCR-ABL1 negative MPDs. This mutation is 
seen in approximately 95% of the patients with PV and in about 50% of 
the patients with ET or PMF (1–5) has led to a radical reassessment of 
MPDs classification, the criteria for diagnosis and perspectives for 
treatment. ET, PV, and PMF share various biological features, which 
suggested a common molecular origin. The most striking similarity is a 
hypersensitivity to erythropoietin (EPO), which leads to the growth of 
erythroid progenitors in vitro in the absence of cytokines (6). 
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1.2 Molecular Biology: 
1.2.1 JAK2 exon 14 mutation: 
The JAK2 gene was first cloned in 1989 and is a member of a family of 
four Janus kinases 1, 2 and 3 and tyrosine kinase2. It was originally 
named just another kinase but the protein group was renamed Janus 
kinases after the Roman God of gates and passages. These non receptors 
kinases have two similar ‘active’ and ‘inactive’ domains and this is 
reminiscent of the God Janus who had the ability to look simultaneously 
in two directions. 
JAK2  is responsible for signal transduction by the erythropoietin, 
thrombopoietin, granulocyte macrophage colony stimulating factor, and 
granulocyte colony-stimulating factor receptors in hematopoietic cells, as 
well as for signal transduction by many cytokine receptors, such as 
interleukin (IL)-3, IL-5, and IL-6 receptors (7). JAK2 is normally 
activated when these receptors bind their cognate ligands erythropoietin, 
thrombopoietin, and granulocyte colony-stimulating factor, granulocyte 
macrophage colony stimulating factor, IL-3, IL-5, or IL-6. However, in 
the myeloproliferative disorders, a point mutation resulting in a switch 
from phenylalanine to valine at amino acid position 671 (V617F) in the 
regulatory domain of the protein releases the adjacent kinase domain 
from inhibition, leading to constitutive activation in the absence of any 
ligand (8).JAK2 is a member of a group of proteins with tyrosine kinase 
activity, the Janus kinases (JAK). These proteins bind the 
intracytoplasmic domain of various cytokine receptors via their FERM 
(4.1 Ezrin Radixin Moesin)-like domain, promoting downstream cell 
signaling (9). JAK2 mediates signaling by various hematopoietic 
receptors comprising the EPO, TPO, and granulocyte colony-stimulating 
factor receptors. JAK2 is also involved in signaling by receptors with 
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tyrosine kinase activity, such as KIT. Following cytokine binding, the 
two JAK2 proteins bound to the cytosolic domain of the receptor are 
activated by transphosphorylation. In turn, they phosphorylate the 
tyrosines of the receptor. This induces the recruitment and 
phosphorylation of actors of signal transduction pathways, such as PI3K, 
RAS complex, and STAT5a/b. Thus, JAK2 mediates cytokine signaling 
to regulate cell proliferation, differentiation, and anti-apoptotic events. 
JAK2 also promotes maturation and is required for the efficient 
trafficking of homodimeric type 1 receptors, such as EPOR (10) and MPL 
(11). JAK2 stabilizes the mature form of MPL and promotes its recycling. 
These two processes are defective in MPNs (12). The mutation may 
disrupt an auto-inhibitory effect of the JH2 domain on the JAK2 kinase 
domain JH1. JAK2V617F is constitutively phosphorylated at the 
activation loop Y1007 and activates downstream signaling pathways 
(JAK2-STAT5, ERK1/2 MAPK and PI-3K/AKT) in a cytokine-
independent or hypersensitive manner (1, 9, 13). 
For the mutant cells, a way to express higher levels of JAK2V617F is to 
duplicate the mutant allele. This duplication is achieved in malignant 
cells from a large proportion of MPD patients. HSC with one 
JAK2V617F allele, also called heterozygous JAK2 wild-type/V617F 
cells, undergo mitotic recombination on the short arm of chromosome 9 
where the JAK2 locus lands (3). By this way, they give rise to a 
homozygous JAK2V617F subclone with two mutant alleles. Intriguingly, 
this phenomenon occurs in some PMF patients and virtually all patients 
with PV but none with ET, as demonstrated by the genotyping of 
individual colonies grown from myeloid progenitors (14, 15). 
All these observations have greatly improved the understanding of the 
pathophysiology of MPD. However, although JAK2V617F positive PV, 
ET, and PMF display differences in terms of clonal architecture, 
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JAK2V617F allele burden, and HSC behavior, the reason why this unique 
mutation is present in such distinct entities remains to be fully elucidated. 
1.2.2 JAK2 exon 12 mutations:  
In the rare JAK2V617F negative PV, Scott et al. (16) described four 
somatic gains of function mutations involving residues 538–543 within 
exon 12. These mutations span a region between the SH2 and JH2 
domains. They include a point mutation (K539L), a double mutation 
(H538QK539L), a 2-amino acid deletion (N542- E543del), and a 2-amino 
acid deletion followed by an insertion (F537-K539delinsL). Other 
mutations in exon 12 have also been described and 15 different acquired 
mutations in the SH2 domain of JAK2 have been published (17). All the 
defects in JAK2 exon 12 lead to a gain of protein functions that confer 
growth factor independency when expressed in the Ba/F3-EPO-R cell 
line. 
Clinically, these mutations are associated with the presence of EEC and a 
low EPO plasma level. Patients with somatic activating missense or 
deletion mutations in exon 12 most commonly present an isolated 
erythrocytosis but not the pan-myeloid expansion seen in JAK2V617F 
positive PV. Therefore, the clinical features of these rare PV are close to 
idiopathic erythrocytosis. The reasons why the diseases induced by 
JAK2V617F and JAK2 exon 12 mutations are phenotypically different 
remains unknown. 
One hypothesis is that the exon 12 mutants induce a higher constitutive 
kinase activity than JAK2V617F and induces polycythemia rather than a 
thrombocytosis. Another hypothesis is that JAK2 exon 12 mutant proteins 
interact preferentially with EPO-R. 
1.2.3 MPL mutations: 
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In 2006, in two studies samples from JAK2V617F negative ET or MF 
patients were examined for mutations in the cytokine receptors that bind 
JAK2 [18, 19]. The authors described a substitution of a somatic 
tryptophan to leucine/ Lysine in position 515 on the TPO receptor MPL 
(MPLW515L/K). Further studies led to the discovery of other mutations 
in the same codon (MPLW515A) [20]. These mutations are present in 5–
10% of patients with primary MF and 2–5% of patients with ET [21].The 
515 amino acid is located in a stretch of five amino acids (K/RWQFP) 
found just after the transmembrane domain. These five amino acids play a 
major role in the cytosolic conformation of MPL and prevent spontaneous 
activation of the receptor. Mutations of W or K (mouse)/R (human) are 
sufficient to activate the receptor [22]. 
As observed for JAK2V617F, these mutations might be present in one or 
two copies. MPLW515 mutants target a HSC capable of reconstituting 
NOD/SCID mice, demonstrating that mutations occur in HSC (23). 
Patients with MPLW515 mutations are characterized by spontaneous MK 
growth with absence of EEC (22). In a murine model, expression of 
MPLW515L leads to a lethal myeloproliferative disorder with 
thrombocytosis and myelofibrosis that is dependent on the JAK2 
activation (19). Recently, it has been shown that a MPLS505N mutation, 
initially described in familial ET, could be also found in sporadic ET or 
PMF (23). 
 
 
1.2.4 C-CBL mutations: 
C-CBL is an E3 ubiquitin ligase that negatively regulates signal 
transduction of activated tyrosine kinases. CBL acts by the ubiquitination 
of various growth factor receptors, which results in their internalization 
and degradation (24). 
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In 2009, acquired uniparental disomies (a UPD) of the long arm of 
chromosome 11 spanning the C-CBL gene were described. CBL 
mutations were then identified in 17% of CMML and in 10% of PMF 
cases (25, 26). 
Subsequently, mutations not only in C-CBL, but also in CBL-B, were 
found in cases of AML transformations of MPD, including CML (27, 28). 
These data indicate that C-CBL mutations can occur in PMF or during the 
progression of MPDs to AML. 
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Justification:                                                                         
Myloproliferative disorders are commonly seen in practice. No 
previous study has been done to describe the clinical and 
haematological features in Sudanese patients. The JAK2 
mutation has been shown to occur in most of MPDs and some 
studies has shown a correlation of the presence of the mutation 
to the clinical course and severity of the disease. 
This study aims to look into this possible link between JAK2 and 
clinical severity of the disease in order to determine the 
significance of doing this test in Sudanese patients for the 
purpose of better management.   
 
 
 
 
12 
 
Objectives: 
General Objectives: 
• To study the clinical and haematological features and to 
look for JAK 2 mutation in Sudanese patients with 
myeloproliferative disorders. 
 
Specific objectives 
• To describe the clinical features of MPDs in Sudanese 
patients.  
• To describe the haematological features of MPDs in 
Sudanese patients.  
• To detect the presence of the JAK 2 mutation in 
Sudanese patients with MPDs.  
• To correlate JAK2 mutation to clinical course of the 
disease. 
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Material and methods 
 
Methodology:  
Study design:     
Cross sectional descriptive study.                                                          
Study area:                                                                                      
Radioisotopes Centre Khartoum (RICK) haematology clinic 
and Fedail Medical Centre (FMC) haematology clinic (May-August) 
2010. 
Study population:                                                                            
Inclusion criteria:                                                                            
1- All patients attending RICK and FMC haematology clinics and 
previously diagnosed or suspected to have polycythaemia, essential 
thrombocythaemia and idiopathic myelofibrosis and who accepted 
to participate in the study.                                                                            
   All ages will be included. - 
2- Males and females.                                                                        
3- Exclusion criteria: 
Patients with Ph positive CML. 
Sampling:                                                                                        
Sample size:                                                                                    
 Fifty patients.                                                                                          
Sample tools:                                                                                  
1- Questionnaire.                                                                                         
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2- Physical examination.                                                                           
3- Laboratory techniques.                                                                        
Study subject (Cases Selection): 
The samples for this study were collected from patients who were 
referred for investigation of one or more of the following: high 
hemoglobin level, high platelets count, neutrophilia, or hematological 
finding suggestive of MPN. A peripheral blood samples of  
50 cases of were evaluated. Cases were classified according to the W.H.O 
criteria as one of the following: P.V (---cases), E.T (---cases), PMF (---
cases).  
Samples Collection:  
Whole blood samples were collected in EDTA anticoagulant containers 
in ratio of 1.5 mg EDTA to 1.0 ml blood. 
Laboratory analysis: 
1- Complete blood count (CBC).  
2- Molecular analysis: DNA was isolated from collected sample using 
Promega purification kits, following  DNA isolation PCR was used to 
amplify JAK2 gene. PCR amplified products were analyzed using gel 
electrophoresis.   
Extraction of human  DNA from Whole  blood  using  Promega  kits 
method. 
 2.2Materials:  
1. Cell lyses buffer solution.  
2.Nucleus lyses  solution. 
3.Protein precipitation solutions. 
4.Iso-propanol. 
5. 70% Ethanol. 
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6. DNA rehydration solution.  
2.3 Methods: 
Five ml of blood was collected from each participant, in EDTA 
containers and DNA was extracted as follow: 
To 300 µl  blood sample  900 µl of cell lyses solution was added  in 
sterile 1.5 micro centrifuge tube, gently mixed then incubated  for 
10mins, then centrifuged  for 10 minutes and supernatant was discarded. 
The precipitants  were mixed vigorously then nuclei lyses solution was 
added  and  mixed, then centrifuged and the supernatant was transferred 
to 1.5ml micro centrifuge containing 300 µl isopropanol then mixed  and 
centrifuged, supernatant was discarded  and  DNA was washed  using 
70%  ethanol  and  rehydration solution was  added  to the DNA and 
stored  at 2-8ºC. 
Method of PCR:  
DNA Amplification and Analysis: 
Equipment and reagents 
1- Themo cycler. 
2- PCR plate with 96 wells. 
3- 1.0 µmol/l set of primers/  
Forward outer (FO), 5_TCCTAGAACGTTGGCAG_3;  
Reverse outer (RO), 5-ATTGCTTTCCTTTTCACAAGAT-3; and 0.5 
µlmol/l  
forward wild-type-specific (Fwt), 5-
GCATTTGGTTTTAAATTATGGAGTAaTG-3; and 
reverse-mutant-specific (Rmt) 
5_GTGATCCGTCAAACTGAATTTTCT_3. 
4- 200 µmol/l of dNTPS, 4 mmol/l Mgcl+2. 
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 Amplification: 
The plate was placed in thermo cycler.  The protocol of amplification was 
programmed follow the reaction conditions: denaturation stage  at  95 C  
for 600 Sec;  50C amplification cycles at 95 C for 5 seconds, 55 C for 15 
seconds, and 72 C for 10 seconds. The products of PCR were run in gel 
electrophoresis to see the mutation.  
 2.4 Data Analysis: 
 The collected data were analyzed using SPSS (version 14) computer 
program.    
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Results 
 
  3-1 Demographic Data:                                                               
In this study, we found that 74% of the patients are above 40 years, of 
them 40% above 60 years (table 1). Fig. 1 shows 66% are males while 
44% are females. The study also reveals 44% of the populations are 
unemployed, 28% are employee, 20% are laborers, 4% are students and 
4% are having free business (table 2). Table 3 shows 66% of the patients 
are originally from central Sudan, 20% from the north, 6% from the west 
while no one originated from the east of the Sudan and only 2% from the 
southern part of Sudan.                                            
3-2 Disease Distribution:                                                                               
 Fig.2 shows 78% of the patients had PRV, 18% had ET and 4% had 
primary MF. The study also shows 48% of the patients are new cases (fig. 
3).                                                                                                             
3-3 Clinical Findings:   
The study shows  that among those  patients with PRV who comprises 
78% of the whole sample, 64.1% have presented initially with headache 
and dizziness, 5.13% with headache alone and 30.77% are asymptomatic 
(table 4),  while those with ET 44.45% have presented with headache and 
dizziness, 33.33% with thrombotic complications and 22.22% are 
asymptomatic (table 5), while those with primary MF who comprises 2 
patients, all of them have presented with generalized fatigue  (table 6), 
while (table 7) showed the overall distribution of clinical presentations in 
MPDs. 
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 Table 8 shows  that among those  patients with PRV (39 patients), 
51.28% have presented initially with splenomegaly, 10.26% with 
hepatosplenomegaly, 5.13% with hepatomegaly alone and in 33.33% 
there is no organomegaly  ,  while those with ET(9 patients), 66.67% 
have presented with splenomegaly, 22.22% hepatosplenomegaly and in  
11.11% there is no organomegaly (table 9), while those with primary MF 
(2 patients) 50% of them have presented with hepatosplenomegaly and 
50% with splenomegaly alone (table 10), while (table 11) showed the 
overall distribution of clinical findings in MPDs. 
.                                                                                                         
3-4 Modalities   of Treatment:                                                          
Regarding the modality of treatment the study revealed that  among those  
patients with PRV 58.97% are treated with venisection and hydroxyurea  
28.21% with venisection  alone and 12.82% are with no treatment (table 
12),  while those with ET  66.67% are treated  with hydroxyurea and 
33.33% are with no treatment modality (table 13), while those with 
primary MF all of them are treated  with hydroxyurea, (table 14), while 
(table 15) showed overall distribution of treatment modalities used in 
MPDs,. In addition to that, the study shows 53.8% of the patients with 
PRV were not needed venesection during the last month, while only 
30.8% of the patients were needed to take more than one unit of blood 
(fig.4).                                                                                 
3-5 Laboratory Findings:  
Upon studying the bone marrow of those patients it was showed  that 
among those  patients with PRV 41.03% had no fibrosis, 38.46% had 
grade 1 fibrosis,  17.95% had grade 2 fibrosis  , 2.56% had grade 3 
fibrosis, and no one had grade 4 fibrosis (table 16),  while those with ET 
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no one had grade 0 fibrosis, 22.22% had grade 1 fibrosis,  44.45% had 
grade 2 fibrosis  , 22.22% had grade 3 fibrosis, 11.11% had grade 4 
fibrosis (table 17), while those with primary MF 50% had grade 3 
fibrosis, 50% had grade 4 fibrosis (table 18 ), while the overall 
distribution of grades of bone marrow fibrosis in MPDs (table 19). The 
bone marrows were graded according to Bauermeister grading system 
(29).     
 
         
3-6 Molecular Findings:                                                                                      
 Table 20 shows JAK2V617F is present in 59% of patients with PRV, 
44% of patients with ET and 0% of the 2 patients of the primary MF, P-
value 0.216.  Among those patients with PRV who are JAK2V617F (23 
patients) regarding male patients 0% are below 20 years, 13.04 % 
between positive 20-39 years, 26.10% between 40-59 years and 30.43% 
are above 60 years, regarding female patients 0% is   below 20 years, 
4.35% between 20-39 years, 13.04% between 40-59 years and 13.04% 
are above 60 years. Among those patients with PRV who are  
JAK2V617F negative (16 Patients), regarding male patients 0% are 
below 20 years  12.5% between 20-39 years, 25% between 40-59 years 
and 31.25% are above 60 years, regarding female patients 0% are   below 
20 years  6.25% between 20-39 years, 12.50% between 40-59 years and 
12.50% are above 60 years (table 21).   Among  those patients with ET 
who are  JAK2V617F positive (4 patients), regarding male patients 50% 
are   below 20 years  0% between 20-39 years, 0% between 40-59 years 
and 0% are above 60 years, regarding female patients, 0% are   below 20 
years  25% between 20-39 years, 0% between 40-59 years and 25% are 
above 60 years.  Among  those patients with ET who are  JAK2V617F 
negative (5 patients), regarding male patients 0% are below 20 years  0% 
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between 20-39 years, 0% between 40-59 years and 40% are above 60 
years, regarding female patients, 0% are   below 20 years  0% between 
20-39 years, 20% between 40-59 years and 40% are above 60 years (table 
22).  Among  those patients with primary MF who are  JAK2V617F 
negative  (2 patients), regarding male patients 0% are below 20 years  
50% between 20-39 years, 0% between 40-59 years and 50% are above 
60 years, regarding female patients JAK2V617F negative  and those with 
primary MF JAK2V617F positive no one in this categories (table23).                                  
Table 24 shows among those patients with PRV who are  JAK2V617F 
positive who  (23 patients), regarding bone marrow fibrosis, 43.48% have 
grade 0 fibrosis, 34.78% have grade 1 fibrosis , 17.39% have grade 2 
fibrosis,  4.35% have grade 3 fibrosis and 0% have grade 4 fibrosis , 
while those patients with PRV who are  JAK2V617F negative (16 
patients), regarding bone marrow fibrosis, 37.50% have grade 0 fibrosis, 
43.75% have grade 1 fibrosis , 18.75% have grade 2 fibrosis, 0% have 
grade 3 fibrosis and 0% have grade 4 fibrosis.   Among  those patients 
with ET who are  JAK2V617F positive who  (4 patients), regarding bone 
marrow fibrosis, 0% have grade 0 fibrosis,  0% have grade 1 fibrosis , 
50% have grade 2 fibrosis,  25% have grade 3 fibrosis and 25% have 
grade 4 fibrosis , while those patients with ET  who are  JAK2V617F 
negative (5 patients), regarding bone marrow fibrosis,  0% have grade 0 
fibrosis,  40% have grade 1 fibrosis , 40% have grade 2 fibrosis, 20% 
have grade 3 fibrosis and 0% have grade 4 fibrosis (table 25).  Among 
those patients with primary MF who are JAK2V617F negative (2 
patients), regarding bone marrow fibrosis, 0% have grade 0 fibrosis,  0% 
have grade 1 fibrosis , 0% have grade 2 fibrosis,  50% have grade 3 
fibrosis and 50% have grade 4 fibrosis , while there is no patient with 
primary MF who is JAK2V617F positive in this sample, (table 26), while 
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(table 27) showed the overall correlation between JAK2V617F and 
grades of bone marrow fibrosis.                                           
Figure 5 shows among those patients with PRV who are JAK2V617F 
positive, the mean haemoglobin level for them is 17.04, while those with 
PRV who are JAK2V617F negative the mean haemoglobin level for them 
is 16.74 and the overall mean is 16.92, also, among those patients with 
ET who are JAK2V617F positive, the mean haemoglobin level for them 
is 13.63, while those with ET who are JAK2V617F negative the mean 
haemoglobin level for them is 12.66 and the overall mean is 13.09, in 
addition to that, the table shows among those with primary MF who are 
JAK2V617F negative the mean haemoglobin level for them is 8.5, while  
there is no patient with primary MF who is JAK2V617F positive in this 
sample  and the overall mean is 13.09.   
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Table (1) Age distribution: 
 
 Frequency Percent 
< 20 yrs 2 4.0 
20-40 yrs 11 22.0 
40-60 yrs 17 34.0 
> 60 yrs 20 40.0 
Total 50 100.0 
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Table (2) Occupational distribution : 
 Frequency Percent 
Employee 14 28.0 
Labo  ur 10 20.0 
Student 2 4.0 
Unemployed 22 44.0 
Free Business. 2 4.0 
Total 50 100.0 
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Table (3) Residence distribution: 
 Frequency Percent 
Central 33 66.0 
Northern 10 20.0 
Southern 1 2.0 
Western 6 12.0 
Total 50 100.0 
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Table (4) Clinical presentations of PRV: 
 
Total None Thrombotic 
complication
FatigueHeadache 
& 
Dizziness 
Headache 
% No % No% No %No% No % No 
100 39 30.77 12 0 0 0 0 64.1025 5.132 PRV 
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Table (5) Clinical presentation of ET:-                                                             
Total None Thrombotic 
complication
FatigueHeadache 
& 
Dizziness 
Headache  
% No % No% No %No% No % No 
1009 22.22 2 33.33 3 0 0 44.45 4 0 0 ET 
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Table (6) Clinical presentations of Primary MF:-             
Total None Fatigue Headache & 
Dizziness 
Headache  
% No % No % No % No % No 
1002 0 0 100 2 0 0 0 0 MF 
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Table (7) Overall Distribution of Clinical Presentation in MPDS: 
 
Chi-Square Tests 
  Value P-value 
Pearson Chi-Square .012 .914
 
  
 
 
 
 
 
 
 
Total  None Thrombotic 
complication
Fatigue Headache 
& 
Dizziness 
Headache  
% No % No % No % No % No % No  
78 39 24 12 0 0 0 0 50 25 4 2 PRV 
18 9 4 2 6 3 0 0 8 4 0 0 ET 
4 2 0 0 0 0 4 2 0 0 0 0 MF 
100 50 28 14 6 3 4 2 58 29 4 2 Total 
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Table (8) Clinical findings of PRV:-                                                                  
Total None Hepato 
splenomegaly
HepatomegalySplenomegaly  
% No % No% No % No % No 
100 39 33.33 13 10.26 4 5.13 2 51.28 20 PRV 
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Table (9) Clinical findings of ET:-                                                                     
Total None Hepato 
splenomegaly
HepatomegalySplenomegaly  
% No % No% No % No % No 
100 9 1.111 1 2.222 2 0 0 66.67 6 ET 
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Table (10) Clinical findings of Primary MF: 
 
Total None Hepato 
splenomegaly
HepatomegalySplenomegaly  
% No % No% No % No % No 
1002 0 0 50 1 0 0 05 0 MF 
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Table  (11)  Overall Distribution of  Clinical Findings in MPDS: 
 
                                                                                                                                 
Total None Hepato 
splenomegaly 
HepatomegalySplenomegaly  
% No % No % No % No % No  
78 39 26 13 8 4 4 2 40 20 PRV 
18 9 2 1 4 2 0 0 12 6 ET 
4 2 0 0 2 1 0 0 2 1 MF 
100 50 28 14 14 7 4 2 54 27 Total 
 
 
P-Value Chi-square 
Value 
0.025 3.25 
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Table (12) Treatment Modalities in PRV: 
                                                                                                        
Total None Hydroxyurea 
&Venisection
HydroxureaVenisection  
% No % No% No % No % No 
10039 12.82 5 58.97 23 0 0 28.21 11 PRV 
 
34 
 
 
 
Table (13) Treatment Modalities in ET: 
                                                                                                           
Total None Hydroxyurea 
&Venisection
HydroxureaVenisection  
% No % No% No % No % No 
1009 33.33 3 0 0 66.676 0 0 ET 
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Table (14) Treatment Modalities in Primary MF: 
                                                                                          
Total None Hydroxyurea 
&Venisection
HydroxureaVenisection  
% No % No% No % No % No 
1002 0 0 0 0 100 2 0 0 MF 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
36 
 
Table (15) Overall Distribution of Treatment Modalities used in 
MPDs: 
 
 
 
Total None Hydroxyurea 
&Venisection 
Hydroxurea Venisection  
% No % No % No % No % No  
78 39 10 5 46 23 0 0 22 11 PRV 
18 9 6 3 0 0 12 6 0 0 ET 
4 2 0 0 0 0 4 2 0 0 MF 
100 50 16 8 46 23 16 8 22 11 Total 
 
 
 
 
 
 
 
Chi-Square Tests 
  Value P-value 
Pearson Chi-Square 3.976 .409
 
 
 
 
 
37 
 
 
Table (16) Grades of Bone Marrow Fibrosis in PRV:  
                                                                                                  
Total 4 3 2 1 Zero  
% No % No % No% No% No % No 
10039 0 0 2.561 17.957 38.4615 41.03 16 PPV 
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Table (17) Grades of Bone Marrow Fibrosis in ET:  
                                                                                                  
Total 4 3 2 1 Zero  
% No % No% No% No% No % No 
1009 11.11 1 22.222 44.454 22.22 2 0 0 ET 
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Table (18) Grades of Bone Marrow Fibrosis in MF: 
                                                                                         
Total 4 3 2 1 Zero  
% No % No% No % No % No % No 
1002 50 1 50 1 0 0 0 0 0 0 ET 
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Table (19) Overall Distribution of Grades of Bone Marrow Fibrosis 
in MPDs: 
 
 
 
 
 
 
 
 
 
Chi-Square Tests 
  Value P-value 
Pearson Chi-Square 2.996 .392
 
 
 
 
 
Total 4 3 2 1 Zero  
  % No % No % No % No % No 
78 39 0 0 2 1 14 7 30 15 32 16 PRV  
18 9 2 1 4 2 8 4 4 2 0 0 ET 
4 2 2 1 2 1 0 0 0 0 0 0 MF 
100 50 4 2 8 4 14 7 34 17 32 16 Total 
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Table (20) Distribution of JAK2 mutation according to the 
type of myeloproliferative disorders : 
 
 
Presence of JAK2 mutation by ARMS-
PCR Total 
                Positive                Negative 
No % No % No % 
Diagnosis 
PRV 23 46.0% 16 32.0% 39 78.0% 
ET 4 8.0% 5 10.0% 9 18.0% 
MF 0 .0% 2 4.0% 2 4.0% 
Total 27 54.0% 23 46.0% 50 100.0% 
 
 
 
Chi-Square Tests 
 Value P-value
Pearson Chi-
Square 
3.067 .216 
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Table (21) Distribution of JAK2V617F according to the 
patient’s sex and age range in PRV patients:-                             
Total Female Male  
≥60 40-59 20-39 ≥60 40-59 20-39 <20 
% No% No % No% No% No% No % No % No 
10023 13.043 13.04 3 4.351 30.437 26.10 6 13.04 3 0 0 PRV 
P+ 
10016 12.502 12.50 2 6.251 31.255 25.0 4 12.50 2 0 0 PRV 
N- 
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Table (22) Distribution of JAK2V617F according to the 
patient’s sex and age range in ET patients 
                     
Total Female Male  
≥60 40-59 20-39 ≥60 40-59 20-39 <20 
% No% No % No% No% No% No % No % No 
1004 25 1 0 0 25 1 0 0 0 0 0 0 50 2 ET 
P+ 
1005 40 2 20 1 0 0 40 2 0 0 0 0 0 0 ET 
N- 
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Table (23) Distribution of JAK2V617F according to the 
patient’s sex and age range in MF patients:- 
                            
Total Female Male  
≥60 40-59 20-39 ≥60 40-59 20-39 <20 
% No% No % No% No% No% No % No % No 
1000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 MF 
+ 
1002 0 0 0 0 0 0 50 1 0 0 50 1 0 0 MF 
N- 
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Table (24) Correlation between JAK2V617F and grades of 
fibrosis: 
 
Total 4 3 2 1 Zero  
% No % No % No% No% No % No 
10023 0 0 4.351 17.394 34.788 43.48 10 PRV 
P+ 
10016 0 0 0 0 18.753 43.757 37.50 6 PRV 
N- 
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Table (25) Correlation between JAK2V617F and grades of 
fibrosis: 
                                                                    
Total 4 3 2 1 Zero  
% No % No% No % No % No % No 
1004 25 1 25 1 50 2 0 0 0 0 ET 
P+ 
1005 0 0 20 1 40 2 40 2 0 0 ET 
N- 
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Table (26) Correlation between JAK2V617F and grades of 
fibrosis: 
                                                                     
Total 4 3 2 1 Zero  
% No % No% No % No % No % No 
0 0 0 0 0 0 0 0 0 0 0 0 MF 
P+ 
1002 50 1 50 1 0 0 0 0 0 0 MF 
N- 
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Table (27)  Overall Correlation between  Grades of Bone Marrow 
Fibrosis  and JAK2V617F  in MPDs: 
 
 
Total 4 3 2 1 Zero  
% No % No % No % No % N0 % No 
46 23 0 0 2 1 8 4 16 8 20 10 PRV 
P+ 
32 16 0 0 0 0 6 3 14 7 12 6 PRV N‐ 
8 4 2 1 2 1 4 2 0 0 0 0 ET P+ 
10 5 0 0 2 1 4 2 4 2 0 0 ET N‐ 
0 0 0 0 0 0 0 0 0 0 0 0 MF P+ 
4 2 2 1 2 1 0 0 0 0 0 0 MF N‐ 
100 50 4 2 8 4 22 11 34 17 32 16 Total 
 
 
 
 
Chi-Square Tests 
  Value P-value 
Pearson Chi-Square 11.755 .109
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Figure (1) Sex distribution:- 
Female; 34.0%
Male; 66.0%
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Figure (2) Distribution of myeloproliferative disorders: 
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Figure (3) Disease duration: 
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Figure (4) Number of blood units taken from patients with PRV during 
the last month:‐ 
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Figure (5) Correlation between JAK2V617F and Current 
Haemoglobin level in MPDs: 
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Figure (6) JAKV617F Mutation bands pattern by ARMS: 
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Discussion 
 
 
This study showed that PRV is more prevalent than ET and primary MF. 
Those patients were collected in a period of two months, 39 of the 50 
patients were found to have PRV. This is in agreement with the quoted 
figures of the literature. 
 JAK2V617F was found to be positive in 59% of patients with PRV, 44% 
of patients with ET and none of the 2 patients of the primary MF. 
 Our figures agree with literature reports in that this molecular 
abnormality occurs mostly in PRV. However our figures are significantly 
lower than mentioned figures in the literature, where for example: 
Green et al found that JAK2V617F was present in 97% of patients with 
PRV, 57% of patients with ET and 50% of the patients with primary MF 
(2), and  Vainchenker et al found that JAK2V617F was present in 88 % 
of patients with PRV, 43% of patients with ET and 43% of the patients 
with primary MF(1). 
In addition to that Gilliland et al found that JAK2V617F was present in 
74%of patients with PRV, 43% of patients with ET and 57% of the 
patients with primary MF(4). 
 Also Skoda et al found that JAK2V617F was present in 65% of patients 
with PRV, 32% of patients with ET and 35% of the patients with primary 
MF(3).  
From these results it was apparent that in our study the number of 
JAK2V617F positive case with PRV is much less, while in primary MF 
we did not find a positive cases. This may be explained by the small 
number in our study as compared to these mentioned studies. However it 
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still confirms that the highest incidence of the JAK2V617F occurs in 
PRV. 
In our study erythropoietin level was not measured for patients with PRV 
which may mean that some of the cases may not actually be PRV and 
could be secondary polycythaemia and this may be the reason why our 
figure is lower.  
This study  also showed that there was no obvious correlation between  
those patients with a positive JAK2V617F and their clinical presentation 
severity , but regarding those patients with ET with a positive 
JAK2V617F, all of them were clinically symptomatic, 75% of them (3 
patients) were presented with thrombotic complications, while only 40% 
of the patients with ET with a negative JAK2V617F were symptomatic, 
none of them presented with thrombotic complication, in addition to that, 
the study also revealed that the mean haemoglobin level in patients with 
positive JAK2V617F is significantly higher than those with negative 
JAK2V617F (p-value =0.152), this observation is more prominent among 
those patients with ET (the mean haemoglobin level for ET patients with 
JAK2V617F positive is 13.63, while those with ET who are JAK2V617F 
negative the mean haemoglobin level for them is 12.66). 
Betty Cheung and his colleagues found that the presence of the 
JAK2V617F mutation is associated with higher haemoglobin and 
increased risk of thrombosis in essential thrombocythaemia (30). 
 This observation may explain the presence of higher percentage of 
symptomatic patients with MPDs with a positive JAK2V617F mutation. 
The impact of the mutation in IMF, from a clinical stand, appears 
somewhat less well defined. In a large study of primary myelofibrosis, 
Campbell et al showed that patients with the JAK2 V617F mutation had 
higher neutrophil and white cell counts compared to patients without the 
mutation and overall tended to have a poorer prognosis (32). Tefferi et al 
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looked for the mutation in a variety of patients with primary 
myelofibrosis and found that the mutation was more likely to be present 
in patients with a previous history of PV compared to de novo MF (33). 
In our study we had only two patients with primary MF both of them 
were JAK2V617F negative and they had a mean hemoglobin level of 
8.5g/dl, so it is not possible therefore to draw conclusion in this group.  
The study also showed that 48.0 % of the patients with positive 
JAK2V617F are taking hydroxyurea , while 69.0% of the patients with 
negative JAK2V617F are taking hydroxyurea,  this comprises 58.97% of 
the patients with PRV, 66.67% of the patients with ET and 100% of the 
patients with primary MF, however we do not regard this as a significant 
observation, because most of those patient who were not taking 
hydroxyurea during the study are new cases, and they will probably take 
the drug later during their disease course, but we think the presence of a 
positive JAK2V617F is of great importance  in deciding the introduction 
of hydroxyurea in managing those patients with early bone marrow  
features of MPDs or who have inconclusive bone marrow findings. 
 The study also showed that the administration of hydroxyurea will not 
affect the positivity of JAK2 V617F mutation or reduce JAK2 V617F 
allele burden.  
Elisabetta A, and her colleagues found that Hydroxyurea does not 
appreciably reduce JAK2 V617F allele burden in patients with 
polycythemia vera or essential thrombocythemia (31). 
The study also showed that 67% of the patients with positive 
JAK2V617F are  having some degree of bone marrow fibrosis , the 
majority of them 40%having grade (2 to 4 fibrosis) bone marrow fibrosis 
(17.39% of PRV patients with positive JAK2V617F, 75% of ET with 
positive JAK2V617F and 100% of primary MF with positive 
JAK2V617F) while 73% of the patients with negative JAK2V617F are 
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having some degree of bone marrow fibrosis , only21%of them having 
grade (2 to 4 fibrosis) bone marrow fibrosis (P-value =0.298), although 
this is insignificant observation and there was no current study to evaluate 
this correlation, but the presence of high percentage of significant fibrosis 
among the patients with positive JAK2V617F in comparison with those 
the patients with negative JAK2V617F  may give us a fertile land for 
more subsequent studies and investigations. 
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Conclusion 
 
 
The following conclusion was obtained from the present study on 
haematological, clinical and molecular features of myeloproliferative 
disorders in Sudanese patients:- 
1- PRV is more prevalent than ET and primary MF.                       
2-  MPD is the disease of elderly.                                                          
3- MPD is more prevalent in the central parts of the Sudan while 
much less in the east and south parts of the Sudan. 
4- Prevalence of JAK2V617F in PRV is much less than the 
literature reports. 
5- The presence of JAK2V617F does not make any significant 
difference in the clinical presentation in those patients with PRV. 
6- Regarding patients with ET presence of a positive JAK2V617F 
mutation is associated with increased haemoglobin levels and 
they are associated with increased risk of thrombosis.   
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Recommendations 
 
 
1- JAK2V617F is an important test thus it should be done for 
suspected patients in order to fulfill the WHO criteria for diagnosis 
of MPDs.                                                               
2- Every patient with MPDs should be well investigated including 
BM biopsy, FBC, erythropoietin level and   molecular studies.                                   
3- Other molecular abnormalities which are associated with MPDs 
like JAK2 exon 12 mutation, MPL mutation and C-CBL mutation 
tests should be available at least in the laboratory of the oncology  
specialized hospital. 
4- All investigations encountered in MPDs are expensive, so those 
tests should be supported financially by the government and 
civilian societies. 
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  Serial number                                     
University of Khartoum 
                           Medical Postgraduate Studies Board 
                                     Department of pathology 
                                             Questionnaire  
Name:……………………………………………………………………  
Age   years 
Sex:                                    Male              Female                            
Telephone………………           
Occupation:……………………………….. 
Residence:………………………………………………………………  
Diagnosis:………………………………………………………………           
Duration of disease: New case                  old case                
how  many   years 
Present complaint: headache                       dizziness                  
                                Fatigue                             Others   
Clinical finding: splenomegaly                   hepatomegaly              
others 
Types of medications: venosection              hydroxyurea             
others 
Number of blood units taken in the last month:   
units 
Investigation:Hb level                         g/dl 
 Presence of JAK2 mutation by ARMS- PCR                    
Grade of fibrosis   
Date:……………………                        Signature:…………  
